UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Nature medicine, 2023-02, Vol.29 (2), p.450-457

2023

Volltextzugriff (PDF)

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer

Clinical cancer research, 2021-02, Vol.27 (4), p.1012-1018

2021

Volltextzugriff (PDF)

Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Nature medicine, 2023-12, Vol.29 (12), p.3270-3270

2023

Volltextzugriff (PDF)

Phase 2 Study of Preoperative SABR for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiation Therapy

International journal of radiation oncology, biology, physics, 2023-07, Vol.116 (3), p.611-616

2023

Volltextzugriff (PDF)

Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis

Journal of magnetic resonance imaging, 2015-11, Vol.42 (5), p.1421-1430

2015

Volltextzugriff (PDF)

Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.598-598

2023

Volltextzugriff (PDF)

Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.596-596

2023

Volltextzugriff (PDF)

Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS629-TPS629

2023

Volltextzugriff (PDF)

Abstract PS3-09: The use of magnetic resonance imaging (MRI) in predicting pathological complete response(pCR) in the breast and axilla after the addition of immunotherapy to neoadjuvant systemic therapy (NST)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS3-09-PS3-09

2021

Volltextzugriff (PDF)

Abstract CT040: A Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT040-CT040

2019

Volltextzugriff (PDF)

A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.578-578

2021

Volltextzugriff (PDF)

Coded modulation for noncoherent reception with application to OFDM

IEEE transactions on vehicular technology, 2001-07, Vol.50 (4), p.910-919

2001

Volltextzugriff (PDF)

Coded modulation using differential encoding over Rayleigh fading channels

Conference record of the annual conference - IEEE Vehicular Technology Conference, 1999, Vol.5, p.2525-2529

1999

Volltextzugriff (PDF)

1 – 13 von 13

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(12)
Tagungsberichte
(1)

Sprache

Englisch
(13)

Erscheinungsjahr

n.n

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer

Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Phase 2 Study of Preoperative SABR for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiation Therapy

Heterogeneity in intratumoral regions with rapid gadolinium washout correlates with estrogen receptor status and nodal metastasis

Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT)

Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial

Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial

Abstract PS3-09: The use of magnetic resonance imaging (MRI) in predicting pathological complete response(pCR) in the breast and axilla after the addition of immunotherapy to neoadjuvant systemic therapy (NST)

Abstract CT040: A Phase I trial of talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer

Coded modulation for noncoherent reception with application to OFDM

Coded modulation using differential encoding over Rayleigh fading channels

Suchergebnisse filtern